Supernus Pharmaceuticals Inc
SUPN
查看详细走势图
51.570USD
-0.200-0.39%
收盘 12/26, 16:00（美东）报价延迟15分钟
2.95B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-0.39%
5天
+4.65%
1月
+11.91%
6月
+65.08%
今年开始到现在
+42.62%
1年
+44.86%
查看详细走势图
TradingKey Supernus Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2025-12-24操作建议
Supernus Pharmaceuticals Inc当前公司基本面数据相对非常健康，增长潜力很大。当前估值合理，在药品行业排名17/158位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价60.50。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Supernus Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
6
位分析师
买入
评级
60.500
目标均价
+28.29%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Supernus Pharmaceuticals Inc亮点
亮点风险
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
利润高增长
公司净利润处于行业前列，最新年度总收入661.82M美元
估值低估
公司最新PE估值-153.25，处于3年历史低位
机构减仓
最新机构持股60.19M股，环比减少5.29%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值559.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.95
Supernus Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Supernus Pharmaceuticals Inc简介
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company’s diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. It is also developing a range of product candidates for CNS disorders. Its commercial products that it markets include Qelbree, GOCOVRI, Oxtellar XR, Trokendi XR, APOKYN, XADAGO, MYOBLOC and ONAPGO. Its ONAPGO injection is a subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. It also offers ZURZUVAE (zuranolone) capsules CIV, which is a U.S. FDA-approved oral medicine indicated for the treatment of adults with postpartum depression.
公司代码SUPN
公司Supernus Pharmaceuticals Inc
CEOKhattar (Jack A)
网址https://www.supernus.com
常见问题
Supernus Pharmaceuticals Inc(SUPN)的当前股价是多少？
Supernus Pharmaceuticals Inc(SUPN)的当前股价是 51.570。
Supernus Pharmaceuticals Inc的股票代码是什么？
Supernus Pharmaceuticals Inc的股票代码是SUPN。
Supernus Pharmaceuticals Inc股票的52周最高点是多少？
Supernus Pharmaceuticals Inc股票的52周最高点是57.650。
Supernus Pharmaceuticals Inc股票的52周最低点是多少？
Supernus Pharmaceuticals Inc股票的52周最低点是29.160。
Supernus Pharmaceuticals Inc的市值是多少？
Supernus Pharmaceuticals Inc的市值是2.95B。
Supernus Pharmaceuticals Inc的净利润是多少？
Supernus Pharmaceuticals Inc的净利润为73.86M。
现在Supernus Pharmaceuticals Inc(SUPN)的股票是买入、持有还是卖出？
根据分析师评级，Supernus Pharmaceuticals Inc(SUPN)的总体评级为买入，目标价格为60.500。
Supernus Pharmaceuticals Inc(SUPN)股票的每股收益（EPS TTM）是多少
Supernus Pharmaceuticals Inc(SUPN)股票的每股收益（EPS TTM）是-0.338。
相关品种
